A recent analysis compared the State Street Health Care Select Sector SPDR ETF (XLV) and the Invesco Nasdaq Biotechnology ETF (IBBQ), highlighting their differing risk-reward profiles. As of July 31, 2026, IBBQ delivered a 45.5% one-year return, significantly outpacing broader healthcare funds like XLV, though with greater volatility. XLV, which offers broad exposure to the S&P 500 healthcare sector, has a lower expense ratio of 0.08% and a higher dividend yield of 1.60%, compared to IBBQ's 0.19% expense ratio and 0.79% dividend yield. IBBQ focuses on biotechnology and pharmaceutical companies listed on the Nasdaq, holding 251 stocks, while XLV holds 60 stocks across the healthcare industry. The analysis suggests XLV suits investors seeking stability and higher dividends, while IBBQ is for those comfortable with higher volatility and believing in continued biotech innovation.